---
title: "Betaxolol - Hypertensive Disorder"
sidebar: mydoc_sidebar
permalink: db00195-mesh-d006973-1.html
toc: false 
---


Path ID: `DB00195_MESH_D006973_1`
{% include image.html url="images/db00195-mesh-d006973-1.png" file="db00195-mesh-d006973-1.png" alt="db00195-mesh-d006973-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D015784">MESH:D015784 </a> | betaxolol | Drug |
| <a href="https://identifiers.org/UniProt:P08588">UniProt:P08588 </a> | Beta-1 adrenergic receptor | Protein |
| <a href="https://identifiers.org/reactome:R-HSA-418555">reactome:R-HSA-418555 </a> | G alpha (s) signalling events | Pathway |
| <a href="https://identifiers.org/InterPro:IPR005446">InterPro:IPR005446 </a> | Voltage-dependent calcium channel, L-type, alpha-1 subunit | GeneFamily |
| <a href="https://identifiers.org/CHEBI:17489">CHEBI:17489 </a> | 3,5-cyclic AMP | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0060047">GO:0060047 </a> | heart contraction | BiologicalProcess |
| <a href="https://identifiers.org/HP:0032263">HP:0032263 </a> | Increased blood pressure | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D006973">MESH:D006973 </a> | Hypertensive disorder | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Betaxolol | DECREASES ACTIVITY OF | Beta-1 Adrenergic Receptor |
| Beta-1 Adrenergic Receptor | PARTICIPATES IN | G Alpha (S) Signalling Events |
| G Alpha (S) Signalling Events | INCREASES ABUNDANCE OF | 3,5-Cyclic Amp |
| G Alpha (S) Signalling Events | POSITIVELY REGULATES | Voltage-Dependent Calcium Channel, L-Type, Alpha-1 Subunit |
| Voltage-Dependent Calcium Channel, L-Type, Alpha-1 Subunit | POSITIVELY CORRELATED WITH | Heart Contraction |
| Heart Contraction | POSITIVELY CORRELATED WITH | Increased Blood Pressure |
| 3,5-Cyclic Amp | POSITIVELY CORRELATED WITH | Heart Contraction |
| Increased Blood Pressure | MANIFESTATION OF | Hypertensive Disorder |
|---------|-----------|---------|

Comment: L-type calcium channels are modulated by the adrenergic nervous system, hence betaxolol could indirectly modulate L calcium channels, decreasing heart rate and contraction, ultimately decreasing high blood pressure (https://en.wikipedia.org/wiki/L-type_calcium_channel#Inhibition_and_modulation).

Reference: 
  - [https://go.drugbank.com/drugs/DB00195#mechanism-of-action](https://go.drugbank.com/drugs/DB00195#mechanism-of-action)
  - [https://en.wikipedia.org/wiki/Betaxolol](https://en.wikipedia.org/wiki/Betaxolol)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL423/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL423/)
  - [https://pubchem.ncbi.nlm.nih.gov/compound/2369#section=Pharmacology-and-Biochemistry](https://pubchem.ncbi.nlm.nih.gov/compound/2369#section=Pharmacology-and-Biochemistry)
  - [https://en.wikipedia.org/wiki/CAMP-dependent_pathway#Importance](https://en.wikipedia.org/wiki/CAMP-dependent_pathway#Importance)
